Clinical trials
Other Cancer clinical trials
Below are recruiting other cancer clinical trials, each written for real people, not researchers. We’re tracking 12,916 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07475403RecruitingPhase 2
Immunotherapy guided by urine DNA for high risk bladder cancer
This trial tests a new immunotherapy approach for people with a very high risk type of bladder cancer that hasn't spread into the muscle layer. The treatment is guided by a special urine test that looks for tumor DNA, and it may help if surgery cannot remove all the cancer or you choose not to have your bladder removed.
TianjinAges 18 years+ - NCT06684418Recruiting
AI to find hidden cancer spread in early lung cancer
This trial uses artificial intelligence to predict if early-stage lung cancer has spread to nearby lymph nodes. It aims to help doctors make better treatment decisions for patients with stage 1 lung cancer.
ShanghaiAges 18 years+ - NCT05667857Recruiting
Tracking brain, mood, and quality of life after immunotherapy
This study follows people who have had advanced cancer and are now stable after immunotherapy, to see how thinking, mood, and daily life change over time. Some participants may also do an integrative brain-training program if they have memory or thinking problems.
Brussels, Brussels CapitalAges 18 years+ - NCT06785077Recruiting
Genetic Study in Ovarian Cancer During PARP Inhibitor Therapy
This study looks at the genetic changes in ovarian cancer cells before and during treatment with PARP inhibitors. It aims to understand how these changes may affect treatment response.
MilanAges 18 years+ - NCT05909111Recruiting
Testing a radiation plan for cervical cancer using MRI guidance
This feasibility study tests whether an MRI-guided radiation approach can be used safely and practically for people with certain stages of cervical cancer. It’s meant to help doctors plan radiation more accurately, while checking whether the treatment process works well.
AvignonAges 18 years+ - NCT06782555RecruitingPhase 1/Phase 2
Study of experimental drug combo for advanced cancers
This trial tests a new combination of three drugs—evofosfamide, zalifrelimab, and balstilimab—in people with advanced prostate, pancreatic, or certain head and neck cancers that have stopped responding to standard treatments.
Houston, TexasAges 18 years+ - NCT06601075Recruiting
FDG and FAPI PET Scans for Advanced Colorectal Cancer
This trial uses two types of PET/CT scans (FDG and FAPI) to better see and track colorectal cancer that has spread to the belly lining (peritoneum). It aims to help doctors choose the best treatment by improving how they detect and monitor the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06769828Recruiting
Ga-68-FAPI-46 PET scan for colorectal cancer recurrence with rising CEA
This trial tests a new type of PET scan called Ga-68-FAPI-46 to help find if your colorectal cancer has returned when your CEA levels are rising. It might offer a more accurate way to detect recurrence early.
Taipei, BeitouAges 20–100 - NCT06787911RecruitingPhase 2
Donafenib and immunotherapy before surgery for advanced thyroid cancer
This trial tests a combination of two drugs—donafenib (a targeted therapy) and an immunotherapy (anti-PD-1 antibody)—given before surgery for locally advanced differentiated thyroid cancer. The goal is to shrink the tumor to make surgery easier and more complete. If you have this type of thyroid cancer that is hard to remove completely with surgery alone, this study may be an option.
ShanghaiAges 18–80 - NCT06787625Recruiting
Growing tumor models from colorectal cancer and liver metastases
This study takes samples from colorectal cancer that has spread to the liver and grows them in the lab. The goal is to create models that can help researchers understand the cancer better and find new treatments.
RomeAges 18 years+ - NCT06786949Recruiting
Night shift work and breast cancer risk study
This study looks at whether working night shifts is linked to breast cancer in female health workers. It aims to understand if there is a higher risk for those who work nights.
BolognaAges 20–70 - NCT02253251Recruiting
Study genes linked to cancer risk and how they may be affected
This study looks at tiny genetic changes (called microRNA binding site mutations) to understand how they relate to cancer risk, prevention, and treatment. If you (or close family members) have had cancer, and you meet the study’s other requirements, your genetic information could help researchers learn how to better predict and manage cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT06071013RecruitingPhase 1/Phase 2
Nintedanib plus EGFR inhibitor for EGFR-mutated lung cancer
This trial tests a combination of two drugs—nintedanib and an EGFR inhibitor—for people with EGFR-mutated non-small cell lung cancer whose cancer has stopped responding to their first EGFR inhibitor treatment. The goal is to see if adding nintedanib can help control the cancer again.
TaichungAges 20–70 - NCT07467330RecruitingPhase 3
Breast cancer trial: Adding capecitabine to standard treatment
This trial tests if adding a chemotherapy drug called capecitabine to the combination of dalpiciclib and hormone therapy works better than dalpiciclib and hormone therapy alone for advanced breast cancer that is hormone receptor-positive and HER2-negative. It is for people who have not had these treatments before.
Fuzhou, FujianAges 18 years+ - NCT07465497Enrolling by invitation
Preventing Chemo Brain with Prebiotics and Synbiotics
This trial tests whether taking a special blend of prebiotics and synbiotics (friendly bacteria and food for them) can help prevent or reduce memory and thinking problems that sometimes happen during chemotherapy for breast cancer.
Zapopan, JaliscoAges 18 years+ - NCT07470853RecruitingPhase 1
Study of HWK-016 for advanced ovarian or endometrial cancer
This trial tests a new drug called HWK-016, which is designed to target and deliver medicine directly to cancer cells that have a specific marker (MUC16). It is for people with advanced ovarian or endometrial cancer to see if it can shrink tumors or slow their growth.
Little Rock, ArkansasAges 18 years+ - NCT07466602Recruiting
Using DNA to detect liver cancer return
This trial uses a blood test to check for signs of liver cancer coming back after treatment. It may help find recurrence earlier than standard scans.
Wuhan, HubeiAges 18 years+ - NCT07468851RecruitingPhase 1/Phase 2
Study of HS-10566 for high-risk bladder cancer that hasn't spread into muscle
This study tests a new treatment called HS-10566 for people with a type of bladder cancer that has not reached the muscle layer and is considered high-risk, where the usual treatments have not worked or were not an option. It aims to control the cancer and avoid the need for removing the bladder.
BeijingAges 18 years+ - NCT07465757RecruitingPhase 2
Study of alisertib and paclitaxel for small cell lung cancer
This trial tests a combination of two drugs, alisertib and paclitaxel, for people with small cell lung cancer (SCLC) who have already had at least one type of platinum chemotherapy and an immunotherapy. The goal is to see if this treatment can help shrink tumors or slow the cancer's growth.
AlicanteAges 18 years+ - NCT06788366Recruiting
AI tool to predict outcomes in metastatic lung cancer
This trial is testing whether artificial intelligence can help predict how well people with advanced non-small cell lung cancer (NSCLC) respond to immunotherapy or chemo-immunotherapy. If you have stage IV NSCLC and have started this treatment, your data may help build a better prediction tool.
MilanAges 18 years+ - NCT06627036RecruitingPhase 4
Dermoscopy vs standard marking for skin cancer removal
This trial compares two ways of marking skin before removing a non-melanoma skin cancer: using a special magnifying tool called a dermoscope versus the standard method. The goal is to see which method helps remove the cancer completely the first time.
HullAges 18 years+ - NCT07471451Recruiting
Eating and quality of life after jaw reconstruction
This study looks at how well people can chew, eat, and speak after having jaw or face reconstruction due to cancer. It aims to understand how these functions affect your daily life and happiness.
Clermont-FerrandAges 18 years+ - NCT07464626Recruiting
Art therapy for anxiety and sleep in colorectal cancer patients
This study compares virtual and in-person art therapy to help reduce anxiety, improve psychological well-being, and enhance sleep quality for people with colorectal cancer who are receiving chemotherapy.
Izmir, BalçovaAges 18 years+ - NCT07470658Enrolling by invitation
Surveillance after positive FIT and normal colonoscopy
This trial studies the best way to follow up with people who had a positive FIT stool test (high blood level) but a normal colonoscopy. It aims to find the right schedule for future screening to catch any problems early.
TaipeiAges 45–74
Hear when a new Other Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for other cancer?
- Yes. Clin2 currently lists 12,916 recruiting other cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a other cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a other cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.